Compare ARK Genomic Revolution ETF (ARKG) vs Phillips 66 (PSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Phillips 66 — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Phillips 66 trades at $191.94 (market cap $75.52B). The key difference: Phillips 66 pays a 2.7% dividend while ARK Genomic Revolution ETF pays none, and Phillips 66 is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | PSX | |
|---|---|---|
Sector | Sector/Thematic | Energy |
52-Week High | $43.57 | $189.82 |
52-Week Low | $23.09 | $118.37 |
Market Cap | — | $75.52B |
Enterprise Value | — | $97.49B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Phillips 66 (PSX) trades at $188.36, down 0.77% on the day, with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 18.6 and P/S of 0.57, while recent quarterly earnings have consistently beaten expectations. The company maintains a 14.75% ROE and recently declared a $1.27 quarterly dividend, reflecting management's confidence in cash flow stability.
PSX presents a compelling value opportunity with upside to the $196.57 consensus price target, supported by 57% analyst buy ratings. Key risks include refining margin volatility from Middle East disruptions and declining revenue trends from $170B in 2022 to $132.4B in 2025. The stock's technical overbought condition near resistance at $191 warrants caution despite positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
